EP2262370A4 - Di-fluoro containing compounds as cysteine protease inhibitors - Google Patents

Di-fluoro containing compounds as cysteine protease inhibitors

Info

Publication number
EP2262370A4
EP2262370A4 EP08744863A EP08744863A EP2262370A4 EP 2262370 A4 EP2262370 A4 EP 2262370A4 EP 08744863 A EP08744863 A EP 08744863A EP 08744863 A EP08744863 A EP 08744863A EP 2262370 A4 EP2262370 A4 EP 2262370A4
Authority
EP
European Patent Office
Prior art keywords
containing compounds
protease inhibitors
cysteine protease
fluoro containing
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08744863A
Other languages
German (de)
French (fr)
Other versions
EP2262370A1 (en
Inventor
John O Link
Craig J Mossman
Jie Liu
Soon Hyung Woo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virobay Inc
Original Assignee
Virobay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virobay Inc filed Critical Virobay Inc
Publication of EP2262370A1 publication Critical patent/EP2262370A1/en
Publication of EP2262370A4 publication Critical patent/EP2262370A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP08744863A 2008-04-01 2008-04-01 Di-fluoro containing compounds as cysteine protease inhibitors Withdrawn EP2262370A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/059025 WO2009123623A1 (en) 2008-04-01 2008-04-01 Di-fluoro containing compounds as cysteine protease inhibitors

Publications (2)

Publication Number Publication Date
EP2262370A1 EP2262370A1 (en) 2010-12-22
EP2262370A4 true EP2262370A4 (en) 2011-08-31

Family

ID=41135860

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08744863A Withdrawn EP2262370A4 (en) 2008-04-01 2008-04-01 Di-fluoro containing compounds as cysteine protease inhibitors

Country Status (5)

Country Link
EP (1) EP2262370A4 (en)
JP (1) JP5497732B2 (en)
CN (1) CN102014635B (en)
BR (1) BRPI0822420A2 (en)
WO (1) WO2009123623A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2720692A4 (en) * 2011-06-17 2015-05-20 Virobay Inc Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021487A1 (en) * 2003-08-27 2005-03-10 Merck Frosst Canada Ltd. Cathepsin inhibitors
WO2005028429A2 (en) * 2003-09-18 2005-03-31 Axys Pharmaceuticals, Inc. Haloalkyl containing compounds as cysteine protease inhibitors
WO2005040142A1 (en) * 2003-10-24 2005-05-06 Aventis Pharmaceuticals Inc. Novel keto-oxadiazole derivatives as cathepsin inhibitors
WO2008042968A2 (en) * 2006-10-04 2008-04-10 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163748A0 (en) * 2002-03-05 2005-12-18 Merck Frosst Canada Inc Cathepsin cysteine protease inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021487A1 (en) * 2003-08-27 2005-03-10 Merck Frosst Canada Ltd. Cathepsin inhibitors
WO2005028429A2 (en) * 2003-09-18 2005-03-31 Axys Pharmaceuticals, Inc. Haloalkyl containing compounds as cysteine protease inhibitors
WO2005040142A1 (en) * 2003-10-24 2005-05-06 Aventis Pharmaceuticals Inc. Novel keto-oxadiazole derivatives as cathepsin inhibitors
WO2008042968A2 (en) * 2006-10-04 2008-04-10 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009123623A1 *

Also Published As

Publication number Publication date
EP2262370A1 (en) 2010-12-22
WO2009123623A1 (en) 2009-10-08
BRPI0822420A2 (en) 2014-10-07
JP2011521893A (en) 2011-07-28
JP5497732B2 (en) 2014-05-21
CN102014635A (en) 2011-04-13
CN102014635B (en) 2015-12-16

Similar Documents

Publication Publication Date Title
IL216145A0 (en) Dihydropyrimidinones for use as bace2 inhibitors
EP2272817A4 (en) Pai-1 inhibitor
ZA201100898B (en) Novel inhibitors
EP2139883A4 (en) Hiv-1 protease inhibitors
EP2519508A4 (en) Metalloenzyme inhibitor compounds
ZA200807713B (en) Thiazolyldihydrocyclopentapyrazoles for use as PI3-kinase inhibitors
ZA201103444B (en) Heteroaromatic compounds for use as hif inhibitors
ZA201107636B (en) Protease inhibitors
EP2509956A4 (en) Cysteine protease inhibitors
EP2358692A4 (en) Cysteine protease inhibitors
EP2313426A4 (en) Novel protease inhibitors
IL197965A0 (en) Di-fluoro containing compounds as cysteine protease inhibitors
ZA201102179B (en) Protease inhibitors
EP2361243A4 (en) Haloalkyl containing compounds as cysteine protease inhibitors
HK1140480A1 (en) Cysteine protease inhibitors
ZA200905263B (en) Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors
EP2262370A4 (en) Di-fluoro containing compounds as cysteine protease inhibitors
GB0817425D0 (en) Protease inhibitors
GB0712193D0 (en) Cysteine protease inhibitors
GB0712222D0 (en) Cysteine protease inhibitors
GB0712172D0 (en) Cysteine protease inhibitors
GB0712540D0 (en) Cysteine protease inhibitors
GB0712541D0 (en) Cysteine protease inhibitors
GB0724732D0 (en) Cysteine protease inhibitors
GB0703043D0 (en) Cysteine protease inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101005

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20110728

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/66 20060101ALI20110722BHEP

Ipc: A01N 57/00 20060101AFI20110722BHEP

17Q First examination report despatched

Effective date: 20130513

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VIROBAY, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150602